Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.47 |
| ▸ | ACACA | Q13085 | 9/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9112604 | 0.93 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL9112039 | 0.91 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL15968429 | 0.85 | ACACB (0.61) | ACACBACACA | |
| SCHEMBL9113117 | 0.85 | ACACB (0.61) | ACACBACACA | |
| SCHEMBL9111840 | 0.84 | ACACB (0.64) | ACACBACACA | |
| SCHEMBL16613050 | 0.84 | MAPT (0.41) | ACACBACACAMAPT | |
| SCHEMBL9114852 | 0.80 | ACACB (0.46) | ACACBACACAMAPTTP53SMN1; SMN2 | |
| SCHEMBL9114681 | 0.80 | ACACB (0.46) | ACACBACACAMAPTTP53SMN1; SMN2 | |
| SCHEMBL9112686 | 0.79 | ACACB (0.46) | ACACBACACAMAPTSMN1; SMN2 | |
| SCHEMBL9112868 | 0.79 | ACACB (0.45) | ACACBACACAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649062-B1 | BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | TAKEDA PHARMACEUTICAL (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8729102-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | ACACB 2/4885ACACA 1/4885MAPT 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.